myriamed is now a member of the Network for Pharma Solutions

myriamed is now a member of the Network for Pharma Solutions

We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development.

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.

About NetPhaSol: NetPhaSol is a cooperation network of more than 50 innovative companies and research institutes. The primary focus are the first value chain stages of a drug development cycle - however, further development stages are not excluded. The network offers an attractive performance portfolio in the fields of e.g. drug discovery, target validation, lead optimization and drug targeting to potential customers, partners and investors for participation and cooperation. The portfolio does not only represent the development of its own products and services and their marketing, but should also be attractive to potential customers of contract research or development.

To learn more about NetPhaSol please visit: https://bit.ly/NetPhaSol

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.

The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.

At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This article was published on openPR.

Go back

Copyright 2021 Seaside Media. All Rights Reserved.